PE20150629A1 - Derivados de etinilo como moduladores de la actividad del receptor de mglur5 - Google Patents
Derivados de etinilo como moduladores de la actividad del receptor de mglur5Info
- Publication number
- PE20150629A1 PE20150629A1 PE2015000396A PE2015000396A PE20150629A1 PE 20150629 A1 PE20150629 A1 PE 20150629A1 PE 2015000396 A PE2015000396 A PE 2015000396A PE 2015000396 A PE2015000396 A PE 2015000396A PE 20150629 A1 PE20150629 A1 PE 20150629A1
- Authority
- PE
- Peru
- Prior art keywords
- disease
- modulators
- receptor activity
- phenyletinyl
- methanone
- Prior art date
Links
- 101150087728 Grm5 gene Proteins 0.000 title 1
- 102100038357 Metabotropic glutamate receptor 5 Human genes 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 abstract 1
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000029560 autism spectrum disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 1
- 229940126662 negative allosteric modulator Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12188940 | 2012-10-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20150629A1 true PE20150629A1 (es) | 2015-05-11 |
Family
ID=47049067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2015000396A PE20150629A1 (es) | 2012-10-18 | 2013-10-15 | Derivados de etinilo como moduladores de la actividad del receptor de mglur5 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US9227959B2 (enExample) |
| EP (1) | EP2909180B1 (enExample) |
| JP (1) | JP5989250B2 (enExample) |
| KR (1) | KR101684816B1 (enExample) |
| CN (1) | CN104718192B (enExample) |
| AR (1) | AR093042A1 (enExample) |
| AU (1) | AU2013333988B2 (enExample) |
| BR (1) | BR112015006454A8 (enExample) |
| CA (1) | CA2882520A1 (enExample) |
| CL (1) | CL2015000891A1 (enExample) |
| CO (1) | CO7200248A2 (enExample) |
| CR (1) | CR20150144A (enExample) |
| EA (1) | EA025667B1 (enExample) |
| ES (1) | ES2599553T3 (enExample) |
| IL (1) | IL237380A (enExample) |
| MA (1) | MA38012B1 (enExample) |
| MX (1) | MX2015004898A (enExample) |
| MY (1) | MY168937A (enExample) |
| NZ (1) | NZ705144A (enExample) |
| PE (1) | PE20150629A1 (enExample) |
| PH (1) | PH12015500398A1 (enExample) |
| SG (1) | SG11201501392TA (enExample) |
| TW (1) | TWI490208B (enExample) |
| UA (1) | UA114529C2 (enExample) |
| WO (1) | WO2014060398A1 (enExample) |
| ZA (1) | ZA201500856B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2909178B1 (en) * | 2012-10-18 | 2016-10-05 | F. Hoffmann-La Roche AG | Ethynyl derivatives as modulators of mglur5 receptor activity |
| JP6603334B2 (ja) | 2015-06-03 | 2019-11-06 | エフ．ホフマン−ラ ロシュ アーゲー | エチニル誘導体 |
| WO2017053769A1 (en) * | 2015-09-25 | 2017-03-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Triazole derivatives as p2y14 receptor antagonists |
| ES2897050T3 (es) | 2017-12-08 | 2022-02-28 | Boehringer Ingelheim Int | Derivados de imidazopiridina y el uso de los mismos como medicamento |
| MA53898B1 (fr) | 2018-10-17 | 2023-03-31 | Boehringer Ingelheim Int | Dérivés de 4-pyrazin-2-ylméthyl-morpholine et leur utilisation comme médicament |
| CN112888684B (zh) | 2018-10-17 | 2023-10-10 | 勃林格殷格翰国际有限公司 | 4-嘧啶-5-基甲基-吗啉衍生物及其作为药物的用途 |
| WO2020079042A1 (en) | 2018-10-17 | 2020-04-23 | Boehringer Ingelheim International Gmbh | 4-pyridinylmethyl-morpholine derivatives and the use thereof as medicament |
| US12398143B2 (en) | 2019-06-04 | 2025-08-26 | Boehringer Ingelheim International Gmbh | Imidazopyrazine derivatives and the use thereof as medicament |
| JP7318015B2 (ja) | 2019-06-04 | 2023-07-31 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 特に抑うつ病性障害の処置のための、ｎｒ２ｂネガティブ調節剤としてのプリン誘導体および医薬としてのその使用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW544448B (en) * | 1997-07-11 | 2003-08-01 | Novartis Ag | Pyridine derivatives |
| UA80888C2 (en) * | 2003-06-05 | 2007-11-12 | Hoffmann La Roche | Imidazole derivatives as glutmate receptor antagonists |
| CA2689282A1 (en) * | 2007-06-03 | 2008-12-11 | Vanderbilt University | Benzamide mglur5 positive allosteric modulators and methods of making and using same |
| US8853392B2 (en) * | 2007-06-03 | 2014-10-07 | Vanderbilt University | Benzamide mGluR5 positive allosteric modulators and methods of making and using same |
| US8389536B2 (en) * | 2009-10-27 | 2013-03-05 | Hoffmann-La Roche Inc. | Positive allosteric modulators (PAM) |
| WO2013049255A1 (en) * | 2011-09-26 | 2013-04-04 | Vanderbilt University | Substitued 5-(prop-1-yn-1-yl)picolinamide analogs as allosteric modulators of mglur5 receptors |
-
2013
- 2013-10-15 UA UAA201504680A patent/UA114529C2/uk unknown
- 2013-10-15 AU AU2013333988A patent/AU2013333988B2/en not_active Ceased
- 2013-10-15 CN CN201380053660.XA patent/CN104718192B/zh not_active Expired - Fee Related
- 2013-10-15 SG SG11201501392TA patent/SG11201501392TA/en unknown
- 2013-10-15 ES ES13783003.0T patent/ES2599553T3/es active Active
- 2013-10-15 JP JP2015535066A patent/JP5989250B2/ja not_active Expired - Fee Related
- 2013-10-15 NZ NZ705144A patent/NZ705144A/en not_active IP Right Cessation
- 2013-10-15 PE PE2015000396A patent/PE20150629A1/es active IP Right Grant
- 2013-10-15 EP EP13783003.0A patent/EP2909180B1/en active Active
- 2013-10-15 MY MYPI2015000470A patent/MY168937A/en unknown
- 2013-10-15 EA EA201590699A patent/EA025667B1/ru not_active IP Right Cessation
- 2013-10-15 WO PCT/EP2013/071500 patent/WO2014060398A1/en not_active Ceased
- 2013-10-15 MX MX2015004898A patent/MX2015004898A/es unknown
- 2013-10-15 BR BR112015006454A patent/BR112015006454A8/pt not_active Application Discontinuation
- 2013-10-15 CA CA2882520A patent/CA2882520A1/en not_active Abandoned
- 2013-10-15 KR KR1020157009544A patent/KR101684816B1/ko not_active Expired - Fee Related
- 2013-10-17 TW TW102137560A patent/TWI490208B/zh not_active IP Right Cessation
- 2013-10-17 AR ARP130103764A patent/AR093042A1/es unknown
-
2015
- 2015-02-05 ZA ZA2015/00856A patent/ZA201500856B/en unknown
- 2015-02-16 CO CO15032736A patent/CO7200248A2/es unknown
- 2015-02-23 IL IL237380A patent/IL237380A/en not_active IP Right Cessation
- 2015-02-24 PH PH12015500398A patent/PH12015500398A1/en unknown
- 2015-03-18 CR CR20150144A patent/CR20150144A/es unknown
- 2015-04-09 CL CL2015000891A patent/CL2015000891A1/es unknown
- 2015-04-17 MA MA38012A patent/MA38012B1/fr unknown
- 2015-04-17 US US14/689,375 patent/US9227959B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20150629A1 (es) | Derivados de etinilo como moduladores de la actividad del receptor de mglur5 | |
| PE20141682A1 (es) | Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio | |
| PE20142301A1 (es) | Uracilos sustituidos biciclicamente y uso de los mismos | |
| PE20142186A1 (es) | Derivados biciclicos de pirazinona | |
| EA201400067A1 (ru) | Новая терапевтическая композиция, содержащая апоморфин в качестве активного ингредиента | |
| MX373079B (es) | Uso de antagonistas del receptor de ep4 en el tratamiento de enfermedad de cartílago. | |
| PE20150628A1 (es) | Derivados de etinilo como moduladores de la actividad del receptor mglur5 | |
| PE20080941A1 (es) | Compuestos triciclicos como agonistas del receptor de melatonina | |
| MX2013006768A (es) | Moduladores de receptor de glucagon. | |
| EA201300389A1 (ru) | Оксадиазольные ингибиторы продуцирования лейкотриена | |
| PH12015502692B1 (en) | Ethynyl derivatives as metabotropic glutamate receptor antagonists | |
| PE20090115A1 (es) | Derivados de indol-2-il-piperazin-1-il-metanona | |
| EA201290534A1 (ru) | Бициклические тиазолы в качестве аллостерических модуляторов mglur5 рецепторов | |
| CY1120608T1 (el) | Φαρμακευτικως δραστικες ενωσεις | |
| UA114008C2 (xx) | Похідні етинілу як модулятори активності рецептора mglur5 | |
| RU2016111390A (ru) | Неконкурентные антагонисты никотиновых рецепторов | |
| PE20150708A1 (es) | Derivados de ariletinilo | |
| RU2014122338A (ru) | Неконкурентные модуляторы никотиновых рецепторов | |
| MX2017015043A (es) | Derivados de etinilo. | |
| TH137350A (th) | แอริลเมทธิลเบนโซควินาโซลิโนน สารปรับควบคุมอัลโลสเตอริกแบบบวกของ m1 รีเซพเตอร์ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |